Skip to main content
Clinical Trials/NCT01915927
NCT01915927
Completed
Phase 1

A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease.

William A. Faubion, M.D.1 site in 1 country20 target enrollmentJuly 2013
InterventionsMSC-AFP
DrugsMSC-AFP

Overview

Phase
Phase 1
Intervention
MSC-AFP
Conditions
Perianal Crohn's Disease
Sponsor
William A. Faubion, M.D.
Enrollment
20
Locations
1
Primary Endpoint
To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The investigators propose to study the safety of autologous mesenchymal stromal cell transfer using a biomatrix (the Gore® Bio-A®; Fistula Plug) in a Phase I study using a single dose of 20 million cells. Twenty adult patients (age 18 years or older) with refractory, complicated perianal fistulizing Crohn's disease will be enrolled. Subjects will undergo standard adjuvant therapy including drainage of infection and placement of a draining seton with continuation of pre-existing anti-Crohn's therapy. Six weeks post placement of the draining seton, the seton will be replaced with the MSC loaded Gore® Bio-A® fistula plug as per current clinical practice. The subjects will be subsequently followed for fistula response and closure for 24 months. This is an autologous product derived from the patient and used only for the same patient.

Registry
clinicaltrials.gov
Start Date
July 2013
End Date
December 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
William A. Faubion, M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

William A. Faubion, M.D.

PI

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

1

Only 1 arm: treatment with MSC-AFP

Intervention: MSC-AFP

Outcomes

Primary Outcomes

To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.

Time Frame: 2-24 months

The primary endpoint of this study is to determine the safety and feasibility of using adipose derived, autologous mesenchymal stromal cells (MSC) bound to the Gore® Bio-A® Fistula Plug for treatment of refractory CD perianal fistulae.

Secondary Outcomes

  • To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC(2-24 months)

Study Sites (1)

Loading locations...

Similar Trials